PURPOSE: The aim of our study was to investigate the impact of the ABO blood 
groups and blood-based biomarkers on the growth kinetics of renal angiomyolipoma 
(AML).
METHODS: A total of 124 patients with AML who were followed-up between 2010 and 
2018 were retrospectively reviewed. The patients' characteristics were recorded, 
including age, body mass index (BMI), blood pressure, smoking history, and ABO 
blood group. Baseline laboratory test results, including serum creatinine, AST, 
ALT, platelet, neutrophil and lymphocyte count, were used to calculate the 
estimated glomerular filtration rate (eGFR), neutrophil-to-lymphocyte ratio 
(NLR), platelet-to-lymphocyte ratio (PLR), and De Ritis ratio. The Cox 
regression analysis was used to evaluate the relationship between variables and 
tumor growth.
RESULTS: The study population comprised 71 women and 44 men with a median age of 
47.3 (28-65) years. Among patients classified according to the blood groups, no 
significant differences were observed regarding age, BMI, smoking history, 
co-morbidities, NLR, PLR, De Ritis ratio, eGFR, or tumor size and localisation. 
The mean growth rate from baseline to the last scan was 0.36 ± 0.27 cm, 
0.21 ± 0.21 cm, 0.14 ± 0.11 cm, and 0.19 ± 0.17 cm for blood type O, A, B, and 
AB, respectively. In multivariate analysis, eGFR < 60 (p = 0.044), central tumor 
localisation (p = 0.030), presence of blood group-0 (p = 0.038), and De Ritis 
ratio ≥ 1.24 (p = 0.047) were statistically associated with tumor growth.
CONCLUSION: Our study demonstrates that both the ABO blood groups and the De 
Ritis ratio might represent independent predictors of tumor growth rate in 
patients with renal AML.